Grifols Management

Management criteria checks 2/4

Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth €777.00K. The average tenure of the management team and the board of directors is 6.3 years and 8.5 years respectively.

Key information

Nacho Abia Buenache

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	6.3yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

May 18

Is Grifols (BME:GRF) Using Too Much Debt?

Apr 30

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Nov 18

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Oct 26

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Aug 18

CEO

Nacho Abia Buenache (55 yo)

less than a year

Tenure

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 777.0k
Alfredo Guerra	CFO & VP	17.3yrs	no data	no data
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	no data	no data
Nuria Lapeña	VP of Corporate Treasury	no data	no data	no data
David Bell	Chief Corporate Development	21.3yrs	no data	0.0029% € 167.7k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.3yrs	no data	0.00078% € 44.3k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	no data	no data
Vicente Blanquer Torre	Chief Quality Officer	31.3yrs	no data	0.0066% € 374.6k
Sergio Adell	President of Commercial Tech Support	5.3yrs	no data	no data
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.0022% € 122.2k
Miguel Montblanch	President of Commercial Operations Support	12.3yrs	no data	no data

6.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: GRF's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.7m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 777.0k
Víctor Grifols Deu	Executive Director	8yrs	€1.04m	0.0022% € 122.2k
Juan Twose Roura	Member of the Advisory Committee	9.3yrs	€380.00k	no data
Raimon Grifols Roura	Vice-Chairman	9yrs	€1.04m	0.0060% € 343.9k
Tomas Daga Gelabert	Independent External Director	24.1yrs	no data	0.045% € 2.5m
Inigo Mardones	Independent Director	9yrs	€150.00k	no data
Carina Szpilka Lázaro	Lead Independent Director	9yrs	€150.00k	0.00022% € 12.5k
James Costos	Independent Director	3.6yrs	€138.00k	no data
Albert Coma-Cros	Proprietary Director	less than a year	no data	0.0097% € 552.5k
Enriqueta Font	Independent Director	5yrs	€125.00k	no data
Montserrat Abellana	Independent Director	1.9yrs	€63.00k	no data

8.5yrs

Average Tenure

59yo

Average Age

Experienced Board: GRF's board of directors are considered experienced (8.5 years average tenure).

Grifols Management

Management criteria checks 2/4

Key information

Recent management updates

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Insufficient new directors

Recent updates

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Consensus EPS estimates fall by 12%

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Consensus EPS estimates fall by 54%

Investor sentiment improves as stock rises 19%

Is Grifols (BME:GRF) Using Too Much Debt?

Consensus EPS estimates increase by 31%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 12%

Now 21% undervalued

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Now 20% undervalued

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Insufficient new directors

Price target decreased to €18.53

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Insufficient new directors

Grifols Announces Management Changes

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Second quarter 2022 earnings: Revenues exceed analyst expectations

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Now 21% undervalued after recent price drop

Now 21% undervalued

CEO

Tenure

Leadership Team